U60BA Adverse reaction to carvedilol Adverse reaction to nebivolol ZV14C Personal history of beta-blocker allergy ZVu6i Personal history of allergy to bisoprolol ZVu6o Personal history of allergy to carvedilol ZVu6q Personal history of allergy to nebivolol 8I26. Beta-blocker contraindicated 8I73. Beta-blocker not tolerated 8I2g. to 8I2i. Bisoprolol, Carvedilol, Nebivolol contraindicated 8I7K. to 8I7M. Bisoprolol, Carvedilol, Nebivolol not tolerated 8IAS. to 8IAV. Bisoprolol, Carvedilol, Nebivolol therapy refused 8I36. Beta-blocker therapy refused b43.. SPIRONOLACTONE Patients with LVSD prescribed b45..% EPLERENONE ACE1 or ARB2 and 662f NYHA I therapy and remain 662g NYHA stage II symptomatic (i.e. NYHA II-IV 662h NYHA stage III optimisation) 662i NYHA stage IV 8I2L. Spironolactone contraindicated Patients who remain Adverse reaction to spironolactone symptomatic (ie NYHA II-IV Mineralocorticoid antagonists [aldosterone antagonists] causing after optimisation) of adverse effects in therapeutic use prescribed aldosterone 8I3K0 Spironolactone declined antagonist 8I3K. diuretic declined
U60BA Adverse reaction to carvedilol Adverse reaction to nebivolol ZV14C Personal history of beta-blocker allergy ZVu6i Personal history of allergy to bisoprolol ZVu6o Personal history of allergy to carvedilol ZVu6q Personal history of allergy to nebivolol 8I26. Beta-blocker contraindicated 8I73. Beta-blocker not tolerated 8I2g. to 8I2i. Bisoprolol, Carvedilol, Nebivolol contraindicated 8I7K. to 8I7M. Bisoprolol, Carvedilol, Nebivolol not tolerated 8IAS. to 8IAV. Bisoprolol, Carvedilol, Nebivolol therapy refused 8I36. Beta-blocker therapy refused Patients with LVSD prescribed ACE1 or ARB2 and therapy and remain symptomatic (i.e. NYHA II-IV optimisation) Patients who remain symptomatic (ie NYHA II-IV after optimisation) of prescribed aldosterone antagonist b43.. SPIRONOLACTONE b45..% EPLERENONE 662f NYHA I 662g NYHA stage II 662h NYHA stage III 662i NYHA stage IV 8I2L. Spironolactone contraindicated Adverse reaction to spironolactone Mineralocorticoid antagonists [aldosterone antagonists] causing adverse effects in therapeutic use 8I3K0 Spironolactone declined 8I3K. diuretic declined
CHF%5FFinal%20main%20guide%20Dec%2020121.docx